Introduction:
Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. It offers Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; Toujeo, an insulin glargine; and Afrezza, an inhaled insulin. The company also provides Praluent, a human monoclonal antibody; and Multaq, a multichannel blocker with anti-arrhythmic properties. In addition, it offers Cerezyme, an enzyme replacement therapy to treat gaucher disease; cerdelga, an oral therapy for Gaucher disease Type 1; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis Type 1, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for breast, prostate, gastric, lungs, and head and neck cancer treatment; Eloxatin for the treatment of stage III colon cancer; Thymoglobulin to treat acute rejection; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix/Iscover for atherothrombosis and acute coronary syndrome; Lovenox/Clexane for the treatment of venous thromboembolism; Aprovel/Avapro/Karvea for hypertension and nephropathy; Renagel/Renvela to treat chronic kidney disease; Allegra/Telfast to treat seasonal allergic rhinitis and uncomplicated hives; Stilnox/Ambien/Myslee for insomnia treatment; and Synvisc/Synvisc-One for the treatment of osteoarthritis pain. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.